Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Single Arm, Observational Study to Evaluate the Safety of Dapagliflozin in Type 2 Diabetes Mellitus Patients in China

NCT03156985 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03156985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03156985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Single Arm, Observational Study to Evaluate the Safety of Dapagliflozin in Type 2 Diabetes Mellitus Patients in China
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
August 16, 2017
Completion date
January 27, 2021
Enrollment
3,000 (actual)
Sites
83

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus